51
|
Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, Vinciguerra V, Rosenbluth R, Bosselli B, Cochran C. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990; 8:313-8. [PMID: 2405107 DOI: 10.1200/jco.1990.8.2.313] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
One hundred twenty-two chemotherapy-naive patients with histologically confirmed colorectal adenocarcinoma were entered into a randomized trial comparing infusional fluorouracil (FU) versus cisplatin (CDDP) and FU. In both groups, patients received continuous infusion FU 1,000 mg/m2/d for 5 consecutive days every 4 weeks. Patients randomized to CDDP/FU also received CDDP 20 mg/m2 intravenous (IV) bolus on days 1 to 5 of each cycle. Patients were comparable in terms of age, performance status, baseline laboratory values, dominant sites of measurable disease, and percent of liver involvement. The partial response rate was significantly greater in patients who received CDDP/FU versus FU alone (25% v 3%, P = .001). Patients who received CDDP/FU experienced significantly greater toxicity compared with FU alone: grades 3 and 4 hematologic toxicity occurred in 22% and 0% of patients, respectively (P = .0001); grades 2 to 4 nausea and vomiting occurred in 80% and 15% of patients, respectively (P = .0001). There were no significant differences in either the duration of response (median, 6 and 4.7 months for CDDP/FU and FU groups, respectively) or survival (median 10, and 12 months, respectively). Compared with infusional FU alone, CDDP/FU provided a significantly greater partial response rate with increased toxicity, but it did not improve overall survival in patients with advanced colorectal carcinoma. Therefore, the use of CDDP/FU as routine therapy for the treatment of colorectal carcinoma cannot be recommended.
Collapse
|
52
|
Palasciano G, Portincasa P, Vinciguerra V, Velardi A, Tardi S, Baldassarre G, Albano O. Gallstone prevalence and gallbladder volume in children and adolescents: an epidemiological ultrasonographic survey and relationship to body mass index. Am J Gastroenterol 1989; 84:1378-82. [PMID: 2683739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
To assess the prevalence of gallstone disease and the behavior of gallbladder (GB) volume in childhood and adolescence, an ultrasonographic survey was carried out on 1570 subjects (age range 6-19 yr). Entered in the study were 750 males and 752 females (attendance rate, 95.7%). Gallstones were detected in two females aged 13 and 18 yr, respectively. None of the subjects in the study population had undergone cholecystectomy. The overall prevalence of gallstone disease was equal to 0.13% (0.27% in the female sex). A positive family history for biliary calculous disease was present in one of the two lithiasic girls. A progressive increase of GB volume with age was observed in both sexes, and figures were greater in males, than in age-matched females. A positive and statistically significant relationship was found between GB volume and body mass index (BMI) in both sexes. Obesity was recognized in 188 males (25.3%) and 167 females (25.0%). Obese subjects exhibited larger GB volumes than the nonobese age- and sex-matched controls. The study supports the view of a very low prevalence of gallstone disease in people younger than 20. It also provides information on GB size in relation to age, sex, and BMI.
Collapse
|
53
|
Sternberg CN, Yagoda A, Scher H, Bosl G, Dershaw D, Rosado K, Houston C, Rosenbluth R, Vinciguerra V, Boselli B. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1989; 25:753-4. [PMID: 2523810 DOI: 10.1016/0277-5379(89)90215-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
54
|
Kemeny N, Niedzwiecki D, Reichman B, Botet J, Vinciguerra V, Michaelson R, Rosenbluth R, Deonarine S. Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. Cancer 1989; 63:1065-9. [PMID: 2917309 DOI: 10.1002/1097-0142(19890315)63:6<1065::aid-cncr2820630604>3.0.co;2-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Because of reported synergism between 5-fluorouracil (5-FU) and cisplatin (CDDP) in L1210 leukemic mice and activity of this combination in clinical studies, a trial was initiated in previously untreated patients with advanced colorectal carcinoma. Cisplatin at 20 mg/m2 and 5-FU as a continuous infusion at 1000 mg/m2 were both administered for 5 consecutive days every 4 weeks. Forty-one patients were treated at Memorial Sloan-Kettering Cancer Center (MSKCC) and 46 were treated by the Community Clinical Oncology Program (CCOP) physicians. A 50% reduction in measurable disease was seen in 12 of 35 (34%) MSKCC patients and in nine of 41 (22%) of the CCOP patients with 95% confidence intervals of 0.18 to 0.50 and 0.10 to 0.35 in the two groups, respectively. The predominant toxicities were as follows: nausea and vomiting, 32%; mucositis, 26%; leukocyte counts less than 2000 cells/mm3, 17%; platelet counts less than 25,000 cells/mm3, 8%; and severe neurotoxicity, 5%. Dose attenuation was similar in the two groups. The median survival was 16.4 months for the MSKCC group and 9.6 months for the CCOP group (P = 0.0003). Although the baseline characteristics (age, sex, performance status, and baseline lactic dehydrogenase [LDH] and alkaline phosphatase) were similar, on further examination differences between the two groups were evident. In the MSKCC group, 14% of patients with liver metastases had greater than 50% of their liver involved with tumor whereas this occurred in 41% of the CCOP group (P = 0.03). The LDH values greater than 500 U/l were observed in 10% of patients in the MSKCC group and in 37% of the patients in the CCOP group (P = 0.007). Characteristics which reflect the bulk of disease, such as the percent of liver involvement, need to be analyzed in order to evaluate purported survival differences in randomized and nonrandomized trials of colorectal carcinoma.
Collapse
|
55
|
Botta B, Botta B, Vinciguerra V, C. De Rosa M, Scurria R, Carbonetti A, Ferrari F, Delle Monache G, Misiti D. Studies in Cell Suspension Cultures of Cassia didymobotrya. Part III. The Biotransformation of Chalcones to Flavones and Biflavanones. HETEROCYCLES 1989. [DOI: 10.3987/com-89-5152] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
56
|
Botta B, Botta B, C. De Rosa M, Vinciguerra V, Scurria R, Iacomacci P, Ferrari F, Delle Monache G, Misiti D. Studies in Cell Suspension Cultures of Cassia didymobotrya. Part II. The Biotransformation of Chalcones to Flavonones. HETEROCYCLES 1989. [DOI: 10.3987/com-89-5151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
57
|
Sun T, Eisenberg A, Benn P, Ngu M, Guarino T, Henshall J, Grossman A, Cuomo J, Vinciguerra V. Comparison of phenotyping and genotyping of lymphoid neoplasms. J Clin Lab Anal 1989; 3:156-62. [PMID: 2754532 DOI: 10.1002/jcla.1860030305] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Comparison of phenotyping (PT) and genotyping (GT) of lymphoid neoplasms was performed on 51 specimens including lymph nodes, bone marrows, and body fluids. PT was performed with a flow cytometer using a large monoclonal antibody panel. GT included the testing for gene rearrangements of heavy chain, kappa and lambda light chains, and T-cell receptor beta-chain genes with DNA probes. The results obtained from these two techniques were generally compatible in terms of clonality and cell lineage. Only one case of B-cell lymphoma was not diagnosed by PT but showed gene rearrangement. For T-cell lymphoma, GT offers a more definitive diagnosis than does PT. Biclonality was demonstrated in one case of hairy cell leukemia by GT only. The rearranged band also offers a definitive clonal identification based on electrophoretic mobility. GT can detect a monoclonal population as small as 5% and can be performed on old or fresh specimens. PT requires 20% abnormal cells and a fresh specimen. It is concluded that GT is superior to PT for lymphoid tumor diagnosis, but it should be reserved as a supplementary test at this stage because of its technical complexity.
Collapse
|
58
|
Kreis W, Budman DR, Delli Bovi P, Vinciguerra V. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist. ONKOLOGIE 1988; 11:292-3. [PMID: 2977219 DOI: 10.1159/000216561] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
59
|
Kreis W, Rottach C, Budman DR, Chan K, Schulman P, Allen SL, Weiselberg L, Vinciguerra V. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Cancer Res 1988; 48:5580-4. [PMID: 3166400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Sixteen patients with previously treated acute nonlymphocytic leukemia or chronic myelogenous leukemia in blast crisis were given one to three courses of esorubicin by continuous infusion over 48 h. Dosage levels extended from 35 to 85 mg/m2. Four patients showed partial responses of short duration. Nonhematological toxicity observed at dosages of 55 to 85 mg/m2 were mucositis, diarrhea, skin rash, transaminitis, nausea, vomiting, and cardiac dysfunction. One patient receiving 85 mg/m2 developed acute florid congestive heart failure within hours of administration of the drug. Pharmacokinetic analysis revealed large interpatient variation in plasma drug levels. At the end of infusion, plasma decay of esorubicin was rapid initially but slow thereafter, with a terminal half-life of 20 to 54 h. The metabolite 4'-deoxy-13-hydroxydoxorubicin reached significant plasma levels. Total body clearance, renal clearance, volume of distribution at steady state, and mean residence time show little variation during dose escalation for both esorubicin and 4'-deoxy-13-hydroxydoxorubicin. Urinary excretion of esorubicin and 4'-deoxy-13-hydroxydoxorubicin accounted for 10.5 and 1.5%, respectively, of the administered dose.
Collapse
|
60
|
Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. NEW YORK STATE JOURNAL OF MEDICINE 1988; 88:525-7. [PMID: 3231372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
61
|
Vinciguerra V. How it can be done: a pilot project in comprehensive home cancer treatment. J Palliat Care 1988; 4:53-5. [PMID: 2459355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
62
|
Palasciano G, Baldassarre G, Portincasa P, Vinciguerra V. [Influence of sex and age on the prevalence of gallbladder calculi in a case series of 10,000 patients examined by echography]. LA CLINICA TERAPEUTICA 1987; 121:275-86. [PMID: 2973863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
63
|
Kelsen DP, Buckner J, Einzig A, Magill G, Heelan R, Vinciguerra V. Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract. CANCER TREATMENT REPORTS 1987; 71:329-30. [PMID: 3815400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
64
|
Vinciguerra V, Degnan TJ, Sciortino A, O'Connell M, Moore T, Brody R, Budman D, Eng M, Carlton D. A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients. J Clin Oncol 1986; 4:1521-8. [PMID: 3760919 DOI: 10.1200/jco.1986.4.10.1521] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
A prospective comparative analysis of home and hospital comprehensive treatment for advanced non-ambulatory cancer patients was conducted. Patients were assigned to hospital (group A) and home (group B) treatment groups based on geographic location. Home treatment was provided by the Don Monti Home Oncology Medical Extension (HOME) program. A multidisciplinary health team, including an oncologist, oncology nurse, social worker, dietitian, and medical technologist, was transported to the home in a medically equipped van. Services included physical examinations, pain control, psychosocial interventions, chemotherapy and blood transfusions, nutrition consultation, and bereavement counseling. One hundred seventy-four patients were treated at home and 44 in the hospital. Pretreatment characteristics were similar for both groups, with the exception that age under 50 years was more frequent in the hospital group, and home patients were more likely to have gastrointestinal (GI) cancer. Medical benefits for home treatment included decreased narcotic analgesic requirements, decreased hospitalization and length of stay, and improved measurements of fat stores for female patients. Improved survival for home patients was related to Karnofsky performance status, since there was no difference in survival for sicker patients with lower performance status whether they received home or hospital treatment. Patient and family acceptance of home treatment was excellent. Comprehensive home treatment provided by a multispecialty oncology team is an effective alternative to hospitalization for terminal cancer patients.
Collapse
|
65
|
Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4:838-46. [PMID: 2423652 DOI: 10.1200/jco.1986.4.6.838] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
A randomized clinical trial of combination chemotherapy for patients who relapsed following primary radiation therapy for Hodgkin's disease was conducted from 1975 to 1981 by the Cancer and Leukemia Group B (CALGB). One hundred thirteen patients were prospectively randomized to receive 12 cycles of either CVPP (CCNU, vinblastine, procarbazine, and prednisone), ABOS (bleomycin, vincristine [Oncovin; Lilly, Indianapolis], doxorubicin [Adriamycin, Adria Laboratories, Columbus, Ohio], and streptozotocin), or alternating cycles of CVPP and ABOS. The median length of observation for patients in this report is 4 years. Toxicities of the three treatment programs were primarily hematologic. Frequencies of complete response were 72% for CVPP, 70% for ABOS, and 82% for CVPP/ABOS (P = .37). Females and patients who had nodular sclerosing disease at initial diagnosis had significantly higher complete response rates. The 5-year disease-free survival for the complete responders was 55%; the 5-year overall survival was 60%. There were no significant differences among the treatments on disease-free survival (P = .78) or overall survival (P = .18). Age under 40 years was the only significant positive prognostic factor for disease-free survival (P = .095) and overall survival (P = .003). This study demonstrates no statistically significant advantage for alternating cycles of combination chemotherapy in affecting complete response frequency, disease-free survival, or overall survival as compared with therapy with CVPP or ABOS alone. However, the power to detect differences in these outcome parameters is somewhat limited by the sample sizes.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
66
|
Ventrella F, Baldassarre G, Vinciguerra V. [Therapy of ascites in the cirrhosis patient]. LA CLINICA TERAPEUTICA 1986; 117:329-42. [PMID: 3731739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
67
|
Vinciguerra V, Ventrella F, Carrieri V. [Therapy of hemorrhage caused by the rupture of esophageal varices]. LA CLINICA TERAPEUTICA 1986; 117:343-53. [PMID: 3488169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
68
|
Vinciguerra V, Doronzo F, Tardi S, Vasti MT, Cecere O, Baldassarre G, Palasciano G, Biraghi M. [Echotomographic, colonoscopic and clinical evaluation of syntropium bromide]. MINERVA DIETOLOGICA E GASTROENTEROLOGICA 1986; 32:197-201. [PMID: 3526191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
69
|
Kreis W, Chaudhri F, Chan K, Allen S, Budman DR, Schulman P, Weiselberg L, Freeman J, Deere M, Vinciguerra V. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Cancer Res 1985; 45:6498-501. [PMID: 3864533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The pharmacokinetic parameters of low dose 1-beta-D-arabinofuranosylcytosine (ara-C) infusions were studied in 11 patients, 6 males and 5 females, with a mean age of 68.5 +/- 13.8 (SD) years. The drug was infused to 4 patients with pre-leukemia (refractory anemia with excess blasts), 5 patients with acute myelogenous leukemia, and 2 patients with secondary leukemia due to chemotherapy, at a dosage of 20 mg/m2/day over 21 days. The patients' blood and urine were analyzed for ara-C content by radioimmunoassay. Mean steady state plasma levels of 7.7 +/- 4.7 ng/ml (31.7 +/- 19.3 nM) (n = 189) and a range 0.6 (2.5 nM) (lower limit of assay) to 29.7 ng/ml (122.1 nM), with significant inter- and intra-patient variations, were reached within about 2.7 h. The plasma levels of ara-C decreased rapidly, with a t1/2 alpha of about 12 min following discontinuation of the infusion, followed by a very slow t 1/2 beta of about 19 h. Other parameters (mean values of 10 or 11 patients) were: area under the curve, 182.1 +/- 64.8 ng X day/ml; total body clearance, 188.7 +/- 54.8 liters/h; renal clearance, 3.1 +/- 1.4 liters/h; volume of distribution at steady state, 53,913 +/- 17,626 liters; and recovery of ara-C in urine, 1.43 +/- 0.69% (n = 226) of daily administered ara-C. A linear relationship was observed with administered dose when the mean plasma levels of our study were compared with the ones reported for conventional ara-C infusions. Plasma clearance was comparable to that observed in conventional dose, when the observed values were extrapolated to the dose administered in this study.
Collapse
|
70
|
Vasti MP, Baldassarre G, Acquaviva M, Palmieri VO, Velardi A, Vinciguerra V, Palasciano G. [Effect of coffee, with or without sugar, on the emptying of the gallbladder]. BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE 1985; 61:1121-8. [PMID: 4063100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
71
|
Vinciguerra V, Anderson K, McIntyre OR. Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B. CANCER TREATMENT REPORTS 1985; 69:331-2. [PMID: 3884154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
72
|
Budman DR, Schulman P, Marks M, Vinciguerra V, Weiselberg L, Kreis W, Degnan TJ. Phase I trial of vinzolidine. CANCER TREATMENT REPORTS 1984; 68:979-82. [PMID: 6744350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Vinzolidine is a new, orally active, semisynthetic vinca alkaloid which shows broad anti-tumor activity against murine tumor test systems. This phase I study established a 1 day every 2 week schedule of 35 mg/m2 in good-risk patients and of 30 mg/m2 in poor-risk patients. Maximal tolerated dose was 45 mg/m2 with severe neutropenia, syndrome of inappropriate antidiuretic hormone, and paralytic ileus. Significant antitumor responses were seen in two patients with lymphoma and in one with squamous cell cancer of the lung.
Collapse
|
73
|
Albano O, Carrieri V, Vinciguerra V, Brindicci D, Cecere O, Mossa A, Palasciano G. Ultrasonic findings in Whipple's disease. JOURNAL OF CLINICAL ULTRASOUND : JCU 1984; 12:286-288. [PMID: 6203935 DOI: 10.1002/jcu.1870120511] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
74
|
Schulman P, Budman DR, Weiselberg L, Vinciguerra V, Degnan TJ. Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma. CANCER TREATMENT REPORTS 1983; 67:943-5. [PMID: 6684988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A phase II trial of mitomycin, vinblastine, and cisplatin was undertaken in 26 patients with non-small cell carcinoma of the lung. A major response rate of 46% was seen in measurable and evaluable disease, with a complete response rate of 12%. Median duration of response is 6.5+ months (range, 2.5-19+). Toxic effects included moderate myelosuppression, mild neuropathy, mild azotemia, and severe nausea and vomiting. These results are similar to previously reported studies using vinca alkaloids and cisplatin alone.
Collapse
|
75
|
Abstract
An unusual case of an IgM producing lymphoproliferative disorder is presented. Using immunofluorescent techniques, this study shows that the heavy chain is associated with kappa light chain in some cells, and with lambda light chain in other cells. This indicates the presence of two distinct malignant cell populations in this patient.
Collapse
|
76
|
Schulman P, Kardon N, Weiner R, Vinciguerra V, Budman DR, Weiselberg L, Degnan TJ. Acquired idiopathic sideroblastic anemia: a new chromosomal abnormality. CANCER GENETICS AND CYTOGENETICS 1983; 9:341-5. [PMID: 6871838 DOI: 10.1016/0165-4608(83)90082-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We describe two patients with acquired idiopathic sideroblastic anemia and a terminal deletion of chromosome No. 11. In spite of the marked chromosomal abnormality neither patient has developed acute leukemia.
Collapse
|
77
|
Minerbrook M, Budman DR, Schulman P, Vinciguerra V, Degnan TJ, Coffey E. De novo disseminated intravascular coagulation in angioimmunoblastic lymphadenopathy (AILD). Cancer 1983; 51:1927-30. [PMID: 6831357 DOI: 10.1002/1097-0142(19830515)51:10<1927::aid-cncr2820511028>3.0.co;2-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
An elderly woman with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) presented de novo with DIC in the absence of other etiologic causes for DIC. Complete reversal of the defibrination process occurred with vincristine, methyl-prednisolone, and heparin therapy. This case illustrates that defibrination can occur de novo in the presence of a clinically, although not pathologically, malignant process. AILD should be considered in the differential diagnosis of DIC.
Collapse
|
78
|
Abstract
Cytogenetic studies of bone marrow specimens from 15 patients with dysmyelopoietic syndrome are presented. The group consists of nine patients with refractory anemia with excess of blasts (RAEB), three patients with chronic myelomonocytic leukemia (CMMoL), and three patients with acquired idiopathic sideroblastic anemia (AISA). None of these patients had a prior history of therapeutic or occupational exposure to potential carcinogenic agents, G(TG)-banding revealed clonal abnormalities in nine of the 15 patients. Five of these patients exhibited one or more of the following cytogenetic abnormalities: 5q deletion, -7, +8, or +21. The AISA group appeared to be unique as chromosome abnormalities were seen in two of the three patients and the clinical course in these patients had been prolonged without progression to acute leukemia. No other clinical correlation could be made in the blast RAEB and CMMoL groups, except for possible survival benefit in patients with normal karyotypes.
Collapse
MESH Headings
- Aged
- Anemia, Aplastic/complications
- Anemia, Aplastic/genetics
- Anemia, Sideroblastic/complications
- Anemia, Sideroblastic/genetics
- Bone Marrow/analysis
- Chromosome Aberrations/genetics
- Chromosome Banding
- Chromosome Disorders
- Chromosomes, Human, 21-22 and Y
- Chromosomes, Human, 4-5
- Chromosomes, Human, 6-12 and X
- Female
- Humans
- Leukemia, Myeloid/complications
- Leukemia, Myeloid/genetics
- Male
- Middle Aged
- Syndrome
Collapse
|
79
|
Weiselberg L, Budman DR, Schulman P, Vinciguerra V, Degnan TJ, Pasmantier M. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary. CANCER TREATMENT REPORTS 1982; 66:1675-6. [PMID: 7201885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
80
|
Budman DR, Schulman P, Vinciguerra V, Weiselberg L, Degnan TJ. Anaphylactoid reaction due to AZQ. Cancer Chemother Pharmacol 1982; 8:317. [PMID: 7127664 DOI: 10.1007/bf00254058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
81
|
Abstract
Two patients who presented with acute leukemia of Burkitt's cell type are discussed. Although one patient died within four months of diagnosis, the other has maintained a one year clinical complete remission. The clinical and morphologic picture of Burkitt's leukemia is nonspecific and therefore requires complementary studies including cytochemistry, transmission electron microscopy, cell surface markers and cytogenetics studies to establish diagnosis. Serial bone marrow aspirations with marker analyses may detect relapse at an earlier stage than conventional cytology, allowing therapy to be modified prior to overt clinical relapse.
Collapse
|
82
|
Bloomfield CD, Pajak TF, Glicksman AS, Gottlieb AJ, Coleman M, Nissen NI, Rafla S, Stutzman L, Vinciguerra V, Glidewell OJ, Holland JF. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. CANCER TREATMENT REPORTS 1982; 66:835-46. [PMID: 6176320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Between 1974 and 1977, the Cancer and Leukemia Group B (CALGB) initiated four studies which address current major questions in the therapy for Hodgkin's disease. The efficacy of chemotherapy alone as compared with combined modality therapy in patients with poor-prognostic stages I and II is evaluated in CALGB 7751. Currently, both therapies produce very high complete remission rates in asymptomatic patients; the remission rate is better with combined modality therapy in symptomatic patients. Single and combined modality therapies are compared for stage III patients in CALGB 7451. Complete remission rates have been similar, but relapse-free survival is superior for patients treated with local nodal radiotherapy followed by chemotherapy (P = 0.04). In particular, stage IIIA patients with nodular sclerosis seem to benefit from the inclusion of radiotherapy in their initial treatment. In CALGB 7551, the efficacy of chemotherapy alone versus chemotherapy plus radiotherapy to areas of bulky disease is under study in patients with stages IIIB and IV. Currently, a relapse rate of less than 10% has been seen among sites irradiated, and survival is best for patients treated with radiotherapy bracketed by chemotherapy. Finally, the role of two alternating non-cross-resistant combination chemotherapy programs is being studied in CALGB 7552. Relapse-free and overall survival is better with the doxorubicin-containing regimen than with either the alternating or alternate chemotherapy program. At present, the median followup for each of these studies is less than 5 years. Further observation is required to answer the critical questions relating to prolonged disease-free survival and cure.
Collapse
|
83
|
Budman DR, Schulman P, Vinciguerra V, Degnan TJ. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule. CANCER TREATMENT REPORTS 1982; 66:173-5. [PMID: 7053254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
In a phase I study of spirogermanium, a new azaspiran-germanium compound, 28 patients were given a multiple-dose schedule. When infused over 1 hour, the maximum tolerated single dose of this agent was greater than 120 mg/m2 but significant chronic neurologic toxicity occurred after 1-2 weeks of treatment. Patients with a poor performance status (PS) were the most likely to manifest toxic reactions. Suggested phage II dose levels for infusion treatment with spirogermanium are 120 mg/m2 for patients with a PS of 0-2 and 80 mg/m2 for patients with a PS of 3.
Collapse
|
84
|
Schulman P, Budman DR, Vinciguerra V, Weiselberg L, Abrams S, Degnan T. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma. CANCER TREATMENT REPORTS 1982; 66:171-2. [PMID: 7053253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A role for vinblastine (VBL) in lung cancer has never been clearly defined. Because of recent pharmacokinetic data suggesting a biweekly schedule for VBL and recent antitumor activity shown for vindesine, a phase II trial of divided-dose VBL was initiated. Among 22 evaluable patients, a 27% major response rate was seen, with a median duration of 5.5 months (range 3.5-12+). The major toxic effect was myelosuppression but was easily manageable and tolerated. These results suggest schedule dependency for VBL and open the question of its efficacy in lung cancer.
Collapse
|
85
|
Budman DR, Schulman P, Vinciguerra V, Degnan T. Phase II trial: mitomycin c and methotrexate combination therapy for advanced colorectal carcinoma. CANCER TREATMENT REPORTS 1981; 65:535. [PMID: 7237477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
86
|
Kross J, Schulman P, Kardon N, Budman D, Vinciguerra V, Degnan T. Association of monosomy 7 with myelodysplasia following chemotherapy for Hodgkin's disease: serial observations. CANCER GENETICS AND CYTOGENETICS 1981; 3:155-9. [PMID: 7272993 DOI: 10.1016/0165-4608(81)90071-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Myelodysplasia and acute nonlymphocytic leukemia following therapy for Hodgkin's disease are observed rather frequently. Herein, we describe a patient with this syndrome treated with prolonged chemotherapy (alone), having a monosomy 7 karyotype. Cytogenetic studies were performed serially during the myelodysplasia preceding overt leukemia. Review of the literature and relevance of these findings are discussed.
Collapse
|
87
|
Weiselberg L, Teichberg S, Vinciguerra V, Schulman P, Budman D, Degnan T. Electron microscope cytochemical analysis of chronic myelocytic leukemia: a case report. Cancer 1981; 47:533-6. [PMID: 6939471 DOI: 10.1002/1097-0142(19810201)47:3<533::aid-cncr2820470318>3.0.co;2-k] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A patient with Philadelphia chromosome positive CML was studied to characterize the blast transformation. Peripheral blood and bone marrow at the onset of the blast crisis were evaluated with cytochemistry, chromosome analysis, cell surface markers, terminal transferase assay, and electron microscopy. Although light microscopic examination and cytochemistry suggested lymphoblastic morphology, ultrastructural cytochemistry demonstrated the myelomonocytic features of the transformation. This study suggests that electron microscopic cytochemistry is useful in evaluating the heterogeneous nature of the blast phase of CML.
Collapse
|
88
|
Weiselberg L, Budman D, Vinciguerra V, Schulman P, Degnan TJ. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature. CANCER CLINICAL TRIALS 1981; 4:195-198. [PMID: 7249256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Estrogen receptors have been demonstrated in human hypernephroma (renal cell carcinoma). Antiestrogens have been demonstrated to have antitumor activity in animal models of this disease. A prospective trial of tamoxifen therapy was undertaken in 10 consecutive patients with unresectable hypernephroma. No major responses to tamoxifen were observed. A review of the literature on antiestrogen therapy for this tumor reveals 148 published cases of hypernephroma treated with tamoxifen or nafoxidine. The overall response rate was 7.4%. Antiestrogens appear to have little clinical usefulness in the treatment of advanced hypernephroma.
Collapse
|
89
|
Schulman P, Sun T, Sharer L, Hyman P, Vinciguerra V, Feinstein M, Blanck R, Susin M, Degnan TJ. Meningeal involvement in IgD myeloma with cerebrospinal fluid paraprotein analysis. Cancer 1980; 46:152-5. [PMID: 7388757 DOI: 10.1002/1097-0142(19800701)46:1<152::aid-cncr2820460125>3.0.co;2-i] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Myelomatous meningitis is a rare occurrence in multiple myeloma. We report 2 cases of documented IgD myeloma with cytologic evidence of meningeal involvement in 1 and detailed paraprotein analysis in both. The occurrence of meningeal involvement in this rare form of plasma cell neoplasm may be more common than previously thought.
Collapse
|
90
|
Vinciguerra V, Degnan T, Diener J, Budman D, Schulman P, McCartney J, O'Connell M, Vargas M. Home Oncology Medical Extension: a new home treatment program. CA Cancer J Clin 1980; 30:182-5. [PMID: 6769555 DOI: 10.3322/canjclin.30.3.182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
|
91
|
Abrams SM, Degnan TJ, Vinciguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. ARCHIVES OF INTERNAL MEDICINE 1980; 140:576-577. [PMID: 7362398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Chloramphenicol-induced aplastic anemia is well described in the literature following oral use of the drug. Here we describe the first case we are aware of in which chloramphenicol eye ointment resulted in severe aplastic anemia and, subsequently, death. At least two cases of marrow hypoplasia following use of chloramphenicol eyedrops have been described previously in the literature. The absorption route, its possible relation to the pathogenesis of aplastic anemia, and the two types of marrow toxicity associated with chloramphenicol are reviewed. This case emphasizes the necessity for the same careful consideration for the use of topical preparations that one affords the use of parenterally and orally administered medications.
Collapse
|
92
|
Schulman P, Budman DR, Vinciguerra V, Degnan TJ. Phase I evaluation of divided-dose vinblastine sulfate. Cancer Chemother Pharmacol 1980; 5:67-9. [PMID: 7460196 DOI: 10.1007/bf00578565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The known pharmacokinetics of vinblastine sulfate given by intermittent bolus dictate alternate dose schedules for prolonging the therapeutic levels. Herein, we have tested a divided dose schedule which shows out-patient feasibility, manageable toxicity, and encouraging responses.
Collapse
|
93
|
Palasciano G, Martino D, Sansone F, Vinciguerra V, Scavelli V, Carrieri V. [Echotomography in the diagnosis of abdominal masses]. CHIRURGIA ITALIANA 1979; 31:257-84. [PMID: 549748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The contribution of echotomography in the surgical approach to intra-abdominal masses is illustrated through description of several clinical observations. In order to effect frontal reconstruction of ultrasonic seriography, the authors used a manual-scanning B echotomograph probe working in the range of grays. This technic afforded detection of the intraperitoneal and extraperitoneal abdominal masses under investigation as well as precise definition of their location, size, and nature. Because of its rapidity and painlessness, echotomography should be adopted as firstchoice procedure for the diagnostic exploration of intraabdominal masses. Frontal reconstruction enables the surgeon to verify the topography of said masses with remarkable precision, and hence to plan surgery more intelligently.
Collapse
|
94
|
Sponzilli T, Tarroni P, D'Amico A, Vinciguerra V, Lupinacci L. [Retrobulbar optic neuritis in the course of methimazole therapy (a clinical case)]. RIVISTA DI NEUROBIOLOGIA : ORGANO UFFICIALE DELLA SOCIETA DEI NEUROLOGI, NEURORADIOLOGI E NEUROCHIRURGHI OSPEDALIERI 1979; 25:233-8. [PMID: 554349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
95
|
Kostinas JE, Leone LA, Cuttner J, Vinciguerra V, Green M, De Bellis R, Pajak TF. Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin. CANCER TREATMENT REPORTS 1979; 63:197-200. [PMID: 376132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Patients with stage III and IV melanoma were randomly assigned to receive procarbazine (100 mg/m2, Days 1--10), vinblastine (5 mg/m2, Days 1 and 8), and actinomycin D (0.5 mg/m2, Days 1 and 8) with or without methanol-extracted residue (MER) of bacillus Calmette-Guerin (200 micrograms in five sites). In patients with measurable disease, 20% (eight of 40 patients) responded with only the combination chemotherapy while 15% (six of 39 patients) responded with the MER added. Toxicity was tolerable except for some instances of severe, gastrointestinal toxicity associated with procarbazine. MER as given in this study, failed to either increase the response rate or prolong survival.
Collapse
|
96
|
Hyman PM, Teichberg S, Starrett S, Vinciguerra V, Degnan TJ. Secretion of primary granules from developing human eosinophilic promyelocytes. Exp Biol Med (Maywood) 1978; 159:380-5. [PMID: 216022 DOI: 10.3181/00379727-159-40352] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
97
|
Palakavongs P, Teichberg S, Vinciguerra V, Degnan TJ, Sinlaratana P. Ultrastructural cytochemical analysis of blastic transformation of chronic myelocytic leukemia. Blood 1977; 49:535-47. [PMID: 191121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Ultrastructural cytochemical changes occurring during the blast phase of chronic myelocytic leukemia (CML) are described. Normal developing promyelocytes contain myeloperoxidase (MPO) -positive rough endoplasmic reticulum, nuclear envelope, and Golgi apparatus. All secretory granules of normal promyelocytes are also MPO-positive. In this study we have found abnormal promyelocytes with MPO-positive as well as MPO-negative secretory granules in blast phase CML patients which contrast with the normal pattern of MPO distribution in most CML patients not in the blast phase or in nonleukemic controls. Alkaline phosphatase activity was found in the nuclear envelope of blasts and promyelocytes of one of the blast transformation patients who had a markedly increased leukocyte alkaline phosphatase score. The cytochemical changes in the distribution of MPO suggest that immature leukemic cells may alter their patterns of secretory granule production. Such processes may reflect the emergence of an abnormal clone of cells during the blastic transformation of CML.
Collapse
|
98
|
Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT. A new combination chemotherapy for resistant Hodgkin disease. JAMA 1977; 237:33-5. [PMID: 62854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A new four-drug combination chemotherapeutic regimen (BVDS) was used in the treatment of advanced Hodgkin disease resistant to MOPP (mechlorethamine hydrochloride, vincristine sulfate, procarbazine hydrochloride, and prednisone). The BVDS regimen, consisting of 12 cycles of bleomycin sulfate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and streptozocin (streptozotocin), was administered to ten patients. Responses were seen in five (50%) of these patients. Complete remissions occurred in three (30%). These results suggest that BVDS is an effective alternative regimen to MOPP, and may be of benefit not only to patients resistant to MOPP, but also to newly-diagnosed patients with advanced hodgkin disease when combined sequentially with MOPP.
Collapse
|
99
|
Currimbhoy Z, Vinciguerra V, Palakavongs P, Kuslansky P, Degnan TJ. Fletcher factor deficiency and myocardial infarction. Am J Clin Pathol 1976; 65:970-4. [PMID: 937251 DOI: 10.1093/ajcp/65.6.970] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The case of a patient who, while being treated for an acute myocardial infarction, was found to have Fletcher factor deficiency with a Fletcher factor concentration of less than 1% of normal is described. Fletcher factor deficiency is associated with defects in several interrelated systems, including clotting, fibrinolysis and kinin generation, all of which play a role in the pathogenesis and evolution of infarction. The development of myocardial infarction in a patient who had severe Fletcher factor deficiency emphasizes the importance of alternate pathways for activation of these systems.
Collapse
|
100
|
Case DC, Waldbaum R, Vinciguerra V, Tomao F. Malignant lymphoma with genitourinary symptoms. Urology 1975; 5:654-7. [PMID: 1129894 DOI: 10.1016/0090-4295(75)90122-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Two cases are reported of patients with widespread intra-abdominal malignant lymphoma who althoug they initially presented with urologic complaints had no evidence of direct genitourinary involvement. Transrectal biopsy established the diagnosis in both cases. This unusual presentation of lymphoma is discussed together with a review of urologic involvement. The necessity for accurate diagnosis is stressed since effective treatment with radiation and chemotherapy is available.
Collapse
|